Posts Tagged ‘Chronic Pain’

Preventing Overdoses when Using Methadone to Treat Chronic Pain

Thursday, April 30th, 2009

Video originally created by FDA -- posted by Lawsuit.com on April 9th, 2009

A report from the Institute for Safe Medication Practices lists several reasons for the serious and sometime fatal overdoses that have occurred when methadone is used to treat moderate to severe chronic pain.

ISMP points out that methadone differs from other opioids in a number of ways. For example, methadone remains in the body long after its analgesic effect has worn off. Also, a patient may not experience the full analgesic effect of methadone until 3-5 days of use, so it must be titrated more slowly than other opioids.

And a high degree of tolerance to other opioids does not eliminate the possibility of methadone overdose. ISMP cites two fatalities and a near fatality from prescribing too large a methadone dose for patients who had previously taken high daily doses of Oxycontin or Vicodin. Also, if a patient on methadone stops taking the drug for three consecutive days, the patient may lose tolerance for methadone and be at risk for an overdose if the usual dose is resumed.

Errors have also been reported because of confusion between methadone and other drugs with “look alike” names. In one report, a 17-year old patient with a traumatic brain injury received 25 mg of methadone BID instead of methylphenidate and suffered respiratory arrest.

ISMP also points out that errors can occur because of confusion between mL and mg doses. In one case, a patient had been taking 13 mg/day of methadone, which was prepared in the community pharmacy using a 1 mg/mL methadone concentration. When the patient was hospitalized, the attending physician assumed that the hospital carried the same concentration and prescribed 12 mL of methadone without specifying the dose in mg. The order was filled with a stock solution that contained 10 mg/mL and administered to the patient — an overdose of nearly tenfold. Fortunately the patient vomited most of the medication and survived.

ISMP recommends a number of steps to help prevent these kinds of life-threatening errors. Here are some of them:

• When prescribing methadone for pain, avoid concomitant use of other narcotics, benzodiazepines, and sedatives, because these significantly increase the risk of an adverse event. Prescribe oral liquid doses of methadone in mg, never in mL alone, since several concentrations exist. Include the indication for use when prescribing methadone, to avoid confusion with methylphenidate. Specify the exact time(s) for administration. If the daily dose is taken in the evening one day and then in the morning the next day, this could lead to an overdose.

• When dispensing methadone, use commercially available methadone solutions to prevent compounding errors. Stock only one concentration of oral liquid methadone in the pharmacy, if possible. Accept orders for methadone only when the dose is prescribed in mg. Label all unit-doses with the exact dose, including strength and total volume if it is a liquid, along with the date and time for administration.

• When administering methadone, adhere to standard medication administration times. If a dose is missed, check with the physician before administering it later than originally scheduled. Make sure a pharmacist has reviewed the order before giving the medication to the patient.

• Remind patients to take methadone exactly as prescribed. Instruct them not to start or stop taking any other medications or dietary supplements without talking to their prescriber, because methadone interacts with many other drugs.

• Instruct methadone patients to seek medical attention if they experience symptoms of overdose, such as slow or shallow breathing and extreme sleepiness, or symptoms of arrhythmia.

VN:F [1.5.6_840]
Rating: 0.0/10 (0 votes cast)
VN:F [1.5.6_840]
Rating: 0 (from 0 votes)

Preventing Patient Deaths from Fentanyl Patches (Sept. 2007)

Wednesday, February 25th, 2009

Video originally created by FDA -- posted by Lawsuit.com on September 03, 2008

September 2008- This story originally aired in September 2007. In this special edition of FDA PSN, we are repeating some of the most important safety issues that continue to pose a public health concern.

A recent report from the Institute for Safe Medication Practices (ISMP) warns about the dangers of misprescribing fentanyl transdermal patches, such as Duragesic. ISMP reminds practitioners that these patches are intended only for patients who are opioid-tolerant, and should not be used for acute pain.

ISMP also pointed out other prescribing errors. In some cases, deaths occurred in patients who were prescribed multiple fentanyl patches, resulting in overdose. In other cases the fentanyl was prescribed in addition to other pain medications, such as oxycodone, or it was prescribed for patients with pre-existing respiratory compromise. ISMP points out that sometimes pharmacists have dispensed these prescriptions without questioning them, and nurses have applied the patches without recognizing the prescribing error.

Here are some of ISMP’s recommendations to help avoid these tragic and preventable errors:

• Prescribe fentanyl patches only for patients who are opioid tolerant, and who have chronic pain that is not well-controlled with shorter-acting analgesics. These patches should not be used for postoperative pain, or for pain that’s short-term or intermittent. Pharmacists should ensure that the patient is opioid-tolerant and suffering from chronic pain before dispensing the drug, and should question the prescriber if this is not the case.

• Set dosing limits. For example, pharmacy computer systems could be set to flash an alert if more than 25 mcg per hour has been prescribed as a first-time dose. Also, in evaluating whether the dose is appropriate, take into account other opiates or analgesics that may have been prescribed.

• Educate practitioners and patients to know the signs of overdose, which include respiratory distress, shallow breathing, fatigue, sleepiness, confusion, dizziness and fainting.

• Prescribing errors are not the only cause of deaths and injuries from fentanyl patches. They also occur when patients mis-use the patches. Sometimes patients and family members do not understand that heat can increase absorption of the drug to dangerous levels. So patients should be told to avoid heating pads, electric blankets or hot baths while the patch is in place, and let their doctors know if they develop a temperature above 102 degrees.

• There have also been cases where children found used patches in the trash and applied them to their own bodies, and died as a result. And so patients should be warned to dispose of the patches by folding them in half and flushing them down the toilet.

VN:F [1.5.6_840]
Rating: 0.0/10 (0 votes cast)
VN:F [1.5.6_840]
Rating: 0 (from 0 votes)

Preventing Patient Deaths from Fentanyl Patches

Wednesday, December 3rd, 2008

Video originally created by FDA -- posted by Lawsuit.com on November 18, 2008

September 2008- This story originally aired in September 2007. In this special edition of FDA PSN, we are repeating some of the most important safety issues that continue to pose a public health concern.A recent report from the Institute for Safe Medication Practices (ISMP) warns about the dangers of misprescribing fentanyl transdermal patches, such as Duragesic. ISMP reminds practitioners that these patches are intended only for patients who are opioid-tolerant, and should not be used for acute pain.ISMP also pointed out other prescribing errors. In some cases, deaths occurred in patients who were prescribed multiple fentanyl patches, resulting in overdose. In other cases the fentanyl was prescribed in addition to other pain medications, such as oxycodone, or it was prescribed for patients with pre-existing respiratory compromise. ISMP points out that sometimes pharmacists have dispensed these prescriptions without questioning them, and nurses have applied the patches without recognizing the prescribing error.Here are some of ISMP’s recommendations to help avoid these tragic and preventable errors:• Prescribe fentanyl patches only for patients who are opioid tolerant, and who have chronic pain that is not well-controlled with shorter-acting analgesics. These patches should not be used for postoperative pain, or for pain that’s short-term or intermittent. Pharmacists should ensure that the patient is opioid-tolerant and suffering from chronic pain before dispensing the drug, and should question the prescriber if this is not the case.• Set dosing limits. For example, pharmacy computer systems could be set to flash an alert if more than 25 mcg per hour has been prescribed as a first-time dose. Also, in evaluating whether the dose is appropriate, take into account other opiates or analgesics that may have been prescribed.• Educate practitioners and patients to know the signs of overdose, which include respiratory distress, shallow breathing, fatigue, sleepiness, confusion, dizziness and fainting.• Prescribing errors are not the only cause of deaths and injuries from fentanyl patches. They also occur when patients mis-use the patches. Sometimes patients and family members do not understand that heat can increase absorption of the drug to dangerous levels. So patients should be told to avoid heating pads, electric blankets or hot baths while the patch is in place, and let their doctors know if they develop a temperature above 102 degrees.• There have also been cases where children found used patches in the trash and applied them to their own bodies, and died as a result. And so patients should be warned to dispose of the patches by folding them in half and flushing them down the toilet.

VN:F [1.5.6_840]
Rating: 0.0/10 (0 votes cast)
VN:F [1.5.6_840]
Rating: 0 (from 0 votes)